President and Chief Executive Officer
Paul Lévesque joint Theratechnologies as President and CEO in March 2020, following more than 35 years of experience in the research-based pharmaceutical industry.
Prior to joining Theratechnologies, Paul spent 28 years at Pfizer taking on various marketing and general management roles in Canada, Europe, Asia and the United States, culminating in the lead of the Global Rare Disease Business Unit based in New York City. Along with Pfizer’s Global Head of Research and Development, he was responsible for driving the commercial success and pipeline of the unit.
Paul carries a passion for bringing therapies to patients in areas of unmet medical need. He holds a BSc in biochemistry from Laval University and a Diploma in Management from McGill University.